NanoViricides (NNVC) announced that it has filed an application for “Rare Pediatric Disease Drug” Designation, RPDD, for NV-387 as a Treatment for Measles with the US FDA Office of Orphan Products Development, OPDD. This RPDD application is expected to be joined together with the Orphan Drug Designation application for NV-387 as a Treatment for Measles that the Company has filed in February, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NNVC: